Wegovy® tablets and stomach pain

How the trials count “stomach pain”

Belly pain is recorded under several medical terms. In the US injection table, “abdominal pain” is a bundle that includes upper and lower abdominal pain, gastrointestinal pain, tenderness, discomfort and epigastric discomfort ^[1]. The EU table also uses a grouped term for abdominal pain ^[2]. The trial registry, by contrast, lists individual terms, so the same kind of pain appears as either “abdominal pain” or “abdominal pain upper” ^[3]. The grouped EU figure and the separate registry rows therefore cannot simply be added together or compared one to one.

Tablet figures from OASIS 4

These are the tablet-specific numbers and where each comes from. The registry results were entered by the sponsor, are not peer reviewed, and cover every event that began between weeks 0 and 71 whatever its cause, listing non-serious events only above 5% and serious ones individually ^[3].

Putting the numbers in context

For orientation only, the US injection table shows abdominal pain in 20% on 2.4 mg weekly versus 10% on placebo ^[1]. Those are injection figures from other trials and should not be read as the tablet’s rate. The published OASIS 4 report adds that digestive adverse events overall affected 74.0% on the tablet and 42.2% on placebo ^[4].

The EU product information describes the OASIS 4 digestive events, abdominal pain included, as mostly mild to moderate and brief, and marks abdominal pain as a reaction seen mainly while the dose is being raised ^[2]. Constipation behaved differently: 20.1% on the tablet versus 9.8% on placebo, still mostly mild to moderate but longer-lasting ^[2]. Pain that travels with constipation may not follow the shorter pattern.

The tablet schedule in US section 2.3 climbs from 1.5 mg to 25 mg over about three months to reduce digestive reactions, and lets a prescriber delay a step that is not tolerated; if 25 mg itself is not tolerated, the label describes switching to the 1.7 mg weekly injection ^[1]. The EU text allows staying at the previous dose level if needed ^[2]. These are prescriber decisions. The EU document also notes that people with moderately reduced kidney function may have more digestive effects, and people with gastroparesis more severe ones ^[2].

Four kinds of pain the label treats as warnings

• Pancreatitis: severe, persistent pain in the stomach area, sometimes spreading to the back, with or without nausea or vomiting ^[1]. The label says to stop and contact the prescriber promptly if it is suspected, and the EU text says semaglutide should not be restarted if pancreatitis is confirmed ^[1][2]. OASIS 4 had no cases on the tablet and one on placebo ^[2][3]; in the injection weight trials, adjudicated cases ran at 0.2 per 100 patient-years on Wegovy® against under 0.1 on placebo, and the label applies those findings to the tablet as well ^[1].
• Gallbladder disease: pain in the upper stomach with fever, yellowing of the skin or eyes, or clay-coloured stools ^[1]. The label links gallstones partly to rapid or substantial weight loss but says the excess on Wegovy® remained after accounting for it ^[1].
• Bowel obstruction: reported after marketing as ileus or intestinal blockage, with frequency not known ^[1][2]; the EU leaflet describes it as severe constipation with stomach ache, bloating and vomiting ^[2].
• Appendicitis: reported in 0.5% on Wegovy® versus 0.2% on placebo in the injection weight trials, a finding the label applies to both forms ^[1]. MedlinePlus warns that early appendicitis may cause only mild pain, or none ^[5].

What a large review says about these risks

A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants, covering GLP-1 medicines in general, found a higher risk of gallstones (risk ratio 1.46, about 2 extra cases per 1,000 people) and probably of reflux disease, but probably little or no effect on pancreatitis, bowel obstruction and the other serious digestive or biliary events it examined ^[6]. The analysis is not specific to the tablet, and “little or no effect” across pooled trials does not remove the need to act on warning symptoms in one person.

Belly pain with nothing to do with the tablet

MedlinePlus lists many everyday causes, including constipation, irritable bowel syndrome, food intolerance, food poisoning and stomach flu, and more serious ones such as appendicitis, gallbladder inflammation, kidney stones, ulcers, diverticulitis, hernias, urinary infections and, in women, ectopic pregnancy, ovarian cysts or pelvic infection ^[5]. It points out that how bad the pain feels does not always match how serious the cause is ^[5].

The pattern helps a clinician. Pain across more than half the belly is more typical of a stomach virus, indigestion or gas; pain fixed in one spot suggests a single organ such as the appendix or gallbladder; cramping is often gas or bloating; and colicky pain that comes in waves is typical of kidney stones or gallstones ^[5].

Easing a mild ache: what MedlinePlus lists

For mild abdominal pain, MedlinePlus suggests sipping water or other clear fluids, holding off solid food for the first few hours and, after vomiting, returning slowly to small amounts of mild food. If the pain sits high in the belly after meals, it says antacids may help, especially with heartburn or indigestion, and suggests avoiding citrus, high-fat, fried or greasy food, tomato products, caffeine, alcohol and fizzy drinks ^[5]. It also warns against taking any medicine without talking to your provider first ^[5].

With the tablet, any oral remedy waits until 30 minutes after the morning dose, and the Medication Guide asks you to tell your provider about every over-the-counter product you use ^[1]. MedlinePlus adds that people with diabetes need to check their blood sugar often when managing belly pain at home ^[5]; the US label notes that Wegovy® tablets have not been studied for weight reduction in people with type 2 diabetes ^[1].

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.